{"id":"W2092228974","doi":"10.1038/bjc.2014.244","title":"Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial","year":2014,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"Genentech; Eisai; GlaxoSmithKline; Pfizer; Astellas Pharma; Bristol-Myers Squibb","keywords":"Axitinib; Sorafenib; Medicine; Sunitinib; Internal medicine; Oncology; Renal cell carcinoma; Urology; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000493714,0.0002661667,0.00113293,0.0001609685,0.00007084182,0.00006619444,0.0001889782,0.0001240266,0.0006666904],"category_scores_gemma":[0.0001569586,0.0002485301,0.0004855802,0.0002084937,0.00007934106,0.0001772391,0.00001770816,0.0004607609,0.000004063052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003700939,"about_ca_system_score_gemma":0.000451913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002226447,"about_ca_topic_score_gemma":0.0005957941,"domain_scores_codex":[0.997313,0.0002544981,0.001061367,0.000326187,0.0006636175,0.0003813569],"domain_scores_gemma":[0.9981148,0.0003666053,0.0007102735,0.0002201328,0.0002644842,0.0003237047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7594211,0.001197915,0.0006453716,0.00001864659,0.0003003316,0.001222995,0.0001841382,0.00003784101,0.04348361,5.442968e-7,0.002712027,0.1907755],"study_design_scores_gemma":[0.9012315,0.003991638,0.003569858,0.0002760419,0.0004757605,0.0001377024,0.00008460139,0.00005829041,0.08098451,0.00002039272,0.00893435,0.0002353434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9565151,0.04080908,0.0000942812,0.0002191331,0.0006595432,0.0008512248,0.00006377554,0.00001227491,0.0007755402],"genre_scores_gemma":[0.9945489,0.003301288,0.0004168809,0.0001832732,0.001061479,0.0000780581,0.00004728453,0.00004731024,0.0003155404],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1905402,"threshold_uncertainty_score":0.9999967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02554856447617362,"score_gpt":0.3147698027311995,"score_spread":0.2892212382550259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}